Evaluation of effectiveness of combined supportive treatment for paronychia and pyogenic granulomas, associated with targeted anticancer therapy

Abstract

BACKGROUND: Paronychia and pyogenic granulomas occur in 10–50% of patients treated with epidermal growth receptor (EGFR) inhibitors. Supportive therapy for periungual lesions is challenging, since these adverse reactions are prone to torpidity and frequent relapses.

AIM: to evaluate the effectiveness of supportive treatment for paronychia and pyogenic granulomas ― dermatologic adverse events of EGFR inhibitors, with a combined cream with betamethasone dipropionate, clotrimazole, gentamicin, and betaxolol solution.

MATERIALS AND METHODS: 16 patients with paronychia and pyogenic granulomas associated with EGFR inhibitor therapy were included in a 12-week open-label prospective study. Paronychia and pyogenic granulomas severity assessment was performed with the NCI-CTCAE v. 5.0, a developed 10-point scale. The intensity of pain was assessed with a visual-analogue scale (VAS). The quality of life was assessed with the Dermatology Life Quality Index (DLQI).

RESULTS: A significant improvement of all parameters (p <0.05) was evaluated from week 1, indicating the effective reduction of dermatologic adverse event objective and subjective symptoms, improvement of patient’s quality of life. By the end of the study, 37.5% of patients had complete resolution of lesions, 62.5% of patients had minimal residual erythema. Decrease of pain sensation in the affected periungual folds was observed throughout the study (p <0.05). DLQI score indicated the "small effect" of paronychia and pyogenic granulomas on patient’s life by the end of the study.

CONCLUSIONS: Supportive treatment of paronychia and pyogenic granulomas with a combined cream with betamethasone dipropionate, clotrimazole and gentamicin and a betaxolol 0.25% solution is effective in the management of paronychia and pyogenic granulomas objective and subjective symptoms, has a high tolerability, allows to improve patient’s quality of life and continue targeted therapy without dose reduction. Long-term maintenance of pain sensation after paronychia and pyogenic granulomas resolution underlines the need for additional treatment options that will improve the effectiveness of pain management.

Keywords

dermatologic adverse events / targeted cancer therapy / paronychia / pyogenic granulomas / supportive care / EGFR inhibitors

References

[1] Bolotina LV, Vladimirova LY, Dengina NV, et al. Practical recommendations for the treatment of malignant tumors of the head and neck. Malignant Tumors. 2020;10(3s2-1):93–108. (In Russ). doi: 10.18027/2224-5057-2020-10-3s2-06

[2] Болотина Л.В., Владимирова Л.Ю., Деньгина Н.В., и др. Практические рекомендации по лечению злокачественных опухолей головы и шеи // Злокачественные опухоли. 2020. Т. 10, № 3s2-1. С. 93–108. doi: 10.18027/2224-5057-2020-10-3s2-06

[3] Gordeev SS, Besova NS, Glebovskaya VV, et al. Practical recommendations for the treatment of cancer of the anal canal and skin of the perianal region. Malignant Tumors. 2020;10(3s2-1):440–449. (In Russ). doi: 10.18027/2224-5057-2020-10-3s2-24

[4] Гордеев С.С., Бесова Н.С., Глебовская В.В., и др. Практические рекомендации по лечению рака анального канала и кожи перианальной области // Злокачественные опухоли. 2020. Т. 10, № 3s2-1. С. 440–449. doi: 10.18027/2224-5057-2020-10-3s2-24

[5] Laktionov KK, Artamonova EV, Breder VV, et al. Practical recommendations on drug treatment of non-small cell lung cancer. Malignant Tumors. 2020;10(3s2-1):40–59. (In Russ). doi: 10.18027/2224-5057-2020-10-3s2-02

[6] Лактионов К.К., Артамонова Е.В., Бредер В.В., и др. Практические рекомендации по лекарственному лечению немелкоклеточного рака легкого // Злокачественные опухоли. 2020. Т. 10, № 3s2-1. С. 40–59. doi: 10.18027/2224-5057-2020-10-3s2-02

[7] Fedyanin MY, Achkasov SI, Bolotina LV, et al. Practical recommendations for the drug treatment of colon cancer and rectosigmoid compound. Malignant Tumors. 2020;10(3s2-1):350–391. (In Russ). doi: 10.18027/2224-5057-2020-10-3s2-22

[8] Федянин М.Ю., Ачкасов С.И., Болотина Л.В., и др. Практические рекомендации по лекарственному лечению рака ободочной кишки и ректосигмоидного соединения // Злокачественные опухоли. 2020. Т. 10, № 3s2-1. С. 350–391. doi: 10.18027/2224-5057-2020-10-3s2-22

[9] Polonskaya AS, Shatokhina EA, Kruglova LS. Dermatological adverse events of epidermal growth factor receptor inhibitors: A modern view on an interdisciplinary problem // Tumors Head Neck. 2021;11(4):97–109. (In Russ). doi: 10.17650/2222-1468-2021-11-4-97-109

[10] Полонская А.С., Шатохина Е.А., Круглова Л.С. Дерматологические нежелательные явления ингибиторов рецептора эпидермального фактора роста: современный взгляд на междисциплинарную проблему // Опухоли головы и шеи. 2021. Т. 11, № 4. С. 97–109. doi: 10.17650/2222-1468-2021-11-4-97-109

[11] Lacouture ME, Sibaud V, Gerber PA, et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines. Ann Oncol. 2021;32(2):157–170. doi: 10.1016/j.annonc.2020.11.005

[12] Lacouture M.E., Sibaud V., Gerber P.A., et al. Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines // Ann Oncol. 2021. Vol. 32, N 2. Р. 157–170. doi: 10.1016/j.annonc.2020.11.005

[13] Robert C, Sibaud V, Mateus C, et al. Nail toxicities induced by systemic anticancer treatments. Lancet Oncol. 2015;16(4):e181–e189. doi: 10.1016/S1470-2045(14)71133-7

[14] Robert C., Sibaud V., Mateus C., et al. Nail toxicities induced by systemic anticancer treatments // Lancet Oncol. 2015. Vol. 16, N 4. Р. e181–e189. doi: 10.1016/S1470-2045(14)71133-7

[15] Cubirо X, Planas-Ciudad S, Garcia-Muret MP, Puig L. Topical timolol for paronychia and pseudopyogenic granuloma in patients treated with epidermal growth factor receptor inhibitors and capecitabine. JAMA Dermatol. 2018;154(1):99–100. doi: 10.1001/jamadermatol.2017.4120

[16] Cubirо X., Planas-Ciudad S., Garcia-Muret M.P., Puig L. Topical timolol for paronychia and pseudopyogenic granuloma in patients treated with epidermal growth factor receptor inhibitors and capecitabine // JAMA Dermatol. 2018. Vol. 154, N 1. Р. 99–100. doi: 10.1001/jamadermatol.2017.4120

[17] Yen CF, Hsu CK, Lu CW. Topical betaxolol for treating relapsing paronychia with pyogenic granuloma-like lesions induced by epidermal growth factor receptor inhibitors. J Am Acad Dermatol. 2018;78(6):e143–e144. doi: 10.1016/j.jaad.2018.01.015

[18] Yen C.F., Hsu C.K., Lu C.W. Topical betaxolol for treating relapsing paronychia with pyogenic granuloma-like lesions induced by epidermal growth factor receptor inhibitors // J Am Acad Dermatol. 2018. Vol. 78, N 6. Р. e143–e144. doi: 10.1016/j.jaad.2018.01.015

[19] Sibaud V, Casassa E, D’Andrea M. Are topical beta-blockers really effective “in real life” for targeted therapy-induced paronychia. Support Care Cancer. 2019;27(7):2341–2343. doi: 10.1007/s00520-019-04690-8

[20] Sibaud V., Casassa E., D’Andrea M. Are topical beta-blockers really effective “in real life” for targeted therapy-induced paronychia // Support Care Cancer. 2019. Vol. 27, N 7. Р. 2341–2343. doi: 10.1007/s00520-019-04690-8

[21] Sollena P, Mannino M, Tassone F, et al. Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: Case series and review of the literature. Drugs Context. 2019;(8):212613. doi: 10.7573/dic.212613

[22] Sollena P., Mannino M., Tassone F., et al. Efficacy of topical beta-blockers in the management of EGFR-inhibitor induced paronychia and pyogenic granuloma-like lesions: Case series and review of the literature // Drugs Context. 2019. N 8. Р. 212613. doi: 10.7573/dic.212613

[23] Olamiju B, Bhullar S, Coleman EL, Leventhal JS. Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies. J Am Acad Dermatol. 2021;84(3):806–808. doi: 10.1016/j.jaad.2020.06.010

[24] Olamiju B., Bhullar S., Coleman E.L., Leventhal J.S. Management of paronychia with pseudopyogenic granulomas secondary to epidermal growth factor receptor inhibitors: An assessment of topical timolol and the need for multiple medical and procedural therapies // J Am Acad Dermatol. 2021. Vol. 84, N 3. Р. 806–808. doi: 10.1016/j.jaad.2020.06.010

[25] Liu HL, Chuang CH, Chen CL, et al. Combination of available topical beta-blockers and antibiotic ointment for epidermal growth factor receptor tyrosine kinase inhibitor-induced paronychia and pseudopyogenic granulomas in Taiwan. J Oncol Pharm Pract. 2022;10781552221122051. doi: 10.1177/10781552221122051

[26] Liu H.L., Chuang C.H., Chen C.L., et al. Combination of available topical beta-blockers and antibiotic ointment for epidermal growth factor receptor tyrosine kinase inhibitor-induced paronychia and pseudopyogenic granulomas in Taiwan // J Oncol Pharm Pract. 2022. Vol. 10781552221122051. doi: 10.1177/10781552221122051

[27] Finlay AY, Khan GK. Dermatology life quality index (DLQI) — A simple practical measure for routine clinical use. Clin Andexperimental Dermatology. 1994;19(3):210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x

[28] Finlay A.Y., Khan G.K. Dermatology life quality index (DLQI) — A simple practical measure for routine clinical use // Clin Experimental Dermatology. 1994. Vol. 19, N 3. Р. 210–216. doi: 10.1111/j.1365-2230.1994.tb01167.x

[29] Kochergin NG, Kochergin SN. Indices of the scale of symptoms and quality of life in dermatology. In: Abstracts of scientific papers of the VIII All-Russian Congress of Dermatovenerologists, June 19–22, 2001. Part 1. Moscow; 2001. Р. 148–149. (In Russ).

[30] Кочергин Н.Г., Кочергин С.Н. Индексы шкалы симптомов и качества жизни в дерматологии // Тезисы научных работ VIII Всероссийского съезда дерматовенерологов, 19–22 июня 2001 г. Часть 1. Москва, 2001. С. 148–149.

[31] Glanc S. Biomedical Statistics. Moscow: Praktika; 1998. 460 р. (In Russ).

[32] Гланц С. Медико-биологическая статистика. Москва: Практика, 1998. 460 с.

[33] Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol. 2005;16(9):1425–1433. doi: 10.1093/annonc/mdi279

[34] Segaert S., Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors // Ann Oncol. 2005. Vol. 16, N 9. Р. 1425–1433. doi: 10.1093/annonc/mdi279

[35] Filoni A, Ambrogio F, De Marco A, et al. Topical beta-blockers in dermatologic therapy. Dermatol Ther. 2021;34(4):e15016. doi: 10.1111/dth.15016

[36] Filoni A., Ambrogio F., De Marco A., et al. Topical beta-blockers in dermatologic therapy // Dermatol Ther. 2021. Vol. 34, N 4. Р. e15016. doi: 10.1111/dth.15016

[37] Koroleva IA, Bolotina LV, Gladkov OA, et al. Practical recommendations on drug treatment of dermatological reactions in patients receiving antitumor drug therapy. Malignant Tumors. 2020;10(3s2-2):88–101. (In Russ). doi: 10.18027/2224-5057-2020-10-3s2-42

[38] Королева И.А., Болотина Л.В., Гладков О.А., и др. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию // Злокачественные опухоли. 2020. Т. 10, № 3s2-2. С. 88–101. doi: 10.18027/2224-5057-2020-10-3s2-42

[39] Lu CW, Wang TY, Yen CF, et al. Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: A case-control cohort study. Int J Dermatol. 2021;60(2):179–184. doi: 10.1111/ijd.15099

[40] Lu C.W., Wang T.Y., Yen C.F., et al. Using betaxolol for the prevention of paronychia induced by epidermal growth factor receptor inhibitors: A case-control cohort study // Int J Dermatol. 2021. Vol. 60, N 2. Р. 179–184. doi: 10.1111/ijd.15099

[41] Chisholm KM, Chang KW, Truong MT, et al. β-adrenergic receptor expression in vascular tumors. Mod Pathol. 2012;25(11):1446–1451. doi: 10.1038/modpathol.2012

[42] Chisholm K.M., Chang K.W., Truong M.T., et al. β-adrenergic receptor expression in vascular tumors // Mod Pathol. 2012. Vol. 25, N 11. Р. 1446–1451. doi: 10.1038/modpathol.2012

RIGHTS & PERMISSIONS

Eco-Vector